Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Andrew Schutte | President, CEO & Director | 44.67k | -- | 1991 |
| Dr. Kevin John McElwee Ph.D. | Co-Founder & Chief Scientific Officer | 51.12k | -- | 1970 |
| Mr. David Kwok CPA | Chief Financial Officer | 28.4k | -- | -- |
| Mr. Ben Austring | Chief Legal Officer, Corporate Secretary & COO | 51.12k | -- | -- |
0913693 B.C. Ltd.
- Sector:
- Healthcare
- Industry: Biotechnology
Description
0913693 B.C. Ltd., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy to treat chronic tendon injuries, androgenetic alopecia, and skin aging by restoring cellular function to rejuvenate aging or sun damaged skin, regrow hair, and repair tendons. The company's product candidates include RCH-01, a cell therapy for pattern baldness; RCS-01, a cell therapy for aging or sun damaged skin; and RCT-01, a cell therapy for tendon degeneration. It is also developing DermaPrecise, a dermal injection device. The company has a licensing and collaborative agreement with YOFOTO (China) Health Industry Co. Ltd. to develop and commercialize programs. The company was formerly known as RepliCel Life Sciences Inc. and changed its name to 0913693 B.C. Ltd. in March 2025. 0913693 B.C. Ltd. is based in Vancouver, Canada.
Corporate Governance
Upcoming Events
May 14, 2025 at 8:00 PM UTC - May 19, 2025 at 8:00 PM UTC
0913693 B.C. Ltd. Earnings Date
Recent Events
August 10, 2016 at 12:00 AM UTC
Dividend Date